220 related articles for article (PubMed ID: 23103500)
1. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
2. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
3. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
5. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
6. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
8. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
10. Effects of common antitussive drugs on the hERG potassium channel current.
Deisemann H; Ahrens N; Schlobohm I; Kirchhoff C; Netzer R; Möller C
J Cardiovasc Pharmacol; 2008 Dec; 52(6):494-9. PubMed ID: 19034038
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
[TBL] [Abstract][Full Text] [Related]
12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
13. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
14. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
15. Observations on conducting whole-cell patch clamping of the hERG cardiac K
Kang J; Luo Y; Searles M; Rampe D
J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
[TBL] [Abstract][Full Text] [Related]
16. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
17. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
18. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
19. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
Dubois VF; Casarotto E; Danhof M; Della Pasqua O
Br J Pharmacol; 2016 Oct; 173(19):2819-32. PubMed ID: 27427789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
